bioRxiv · 10.1101/2021.10.18.464924
Triazolopyrimidines target aerobic respiration in Mycobacterium tuberculosis
Abstract
We previously identified a series of triazolopyrimidines with anti-tubercular activity. We determined that Mycobacterium tuberculosis strains with mutations in a component of the cytochrome bc1 system (QcrB) were resistant to the series. A cytochrome bd oxidase deletion strain was also more sensitive to this series. We isolated resistant mutants, all of which had mutations in Rv1339. Compounds were active against intracellular bacteria but did not inhibit mitochondrial respiration in human HepG2 cells. These data are consistent with triazolopyrimidines acting via inhibition of M. tuberculosis QcrB.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Shelton, C. D., McNeil, M. B., Flint, L., Russell, D., Berube, B., Korkegian, A., Ovechkina, Y., Parish, T.. 2021-10-20. Triazolopyrimidines target aerobic respiration in Mycobacterium tuberculosis. https://doi.org/10.1101/2021.10.18.464924
Cite the original work for its findings. Save a collection to share your selection of sources.